MANSFIELD, Mass. - Covidien, a leading global provider of healthcare products, today announced organizational changes to the leadership team of its Vascular Therapies Global Business Unit. According to Stacy Enxing Seng, president of the 4,000 employee, $1.4 billion business, the changes will enhance the customer experience worldwide. Covidien Vascular Therapies offers clinically proven solutions for the prevention and treatment of deep vein thrombosis, chronic venous insufficiency, dialysis access, peripheral vascular disease and neurovascular disease.

"Our vision is to be the clear first choice for patients, customers and employees," said Enxing Seng. "Our leadership team will ensure that we align our commercial, technology and clinical strategies to drive and support the global Vascular business."

The new organization features three divisions:

  • Peripheral Vascular, headed by Brian Verrier, Vice President and General Manager. Since October 2010, Brian led the Venous Vascular division, including the thrombosis, renal access and chronic venous insufficiency businesses. In his new role, Brian will be responsible for those businesses, as well as the plaque excision, peripheral stent and embolic protection business. Prior to joining Covidien, Brian was Vice President, U.S. Sales for Medtronics Coronary and Peripheral Vascular Business, and has over 22 years of experience in the medical device industry.
  • Neurovascular, headed by Brett Wall, President. Based in Irvine, CA, Brett joined the Company as part of the ev3 acquisition and has held roles as head of Vascular Therapies International, ev3 International as well as a variety of other leadership positions within Peripheral Vascular and Neurovascular. Brett joined ev3 as part of the MicroTherapeutics acquisition in 2005. Prior to joining Covidien, he held various global positions including Director of Cardiovascular Marketing, Asia Pacific for Boston Scientific and has over 20 years of experience in the medical device industry.
  • International, headed by Chris Hutchison, Vice President and General Manager. Based in Mansfield, MA, Chris joined Covidien in January 2006 and spent three and a half years in Europe leading the Respiratory and Monitoring Solutions business prior to assuming leadership of the European commercial operations of Vascular Therapies.  Chris returned to the U.S. in July 2010 to work full time on the integration effort following the acquisition of ev3. Prior to joining Covidien, Chris spent nine years with Smiths Group, including four years as President of the U.S. Anesthesia and Safety Device division.

With areas of focus in peripheral vascular, venous vascular and neurovascular, Covidien offers the worlds broadest portfolio of innovative vascular therapies backed by compelling clinical evidence and educational excellence. Covidien Vascular Therapies has a portfolio that includes: dialysis catheters, anti-embolism stockings, systems, plaque excision systems, targeted endovenous therapy, PTA balloons, stents, embolic protection, thrombectomy, embolization coils, liquid embolics, occlusion balloons and procedural support solutions.